ACIP

CDC has expanded recommendations for booster shots to now include all adults ages 18 years and older who received a Pfizer-BioNTech or Moderna (mRNA) COVID-19 vaccine as part of their primary series. Get more information and read CDC’s media statement.

Contact ACIP Secretariat

1600 Clifton Road, N.E., Mailstop H24-8
Atlanta, GA 30329-4027
acip@cdc.gov

email_03Get Email Updates

To receive email updates about this page, enter your email address:

Meeting Recommendations
October 2021

ACIP approved the following recommendations by majority vote at its October 20, 2021 meeting:

  • Two doses of recombinant zoster vaccine are recommended for the prevention of herpes zoster and its complications in adults aged ≥19 years who are or will be immunodeficient or immunosuppressed due to disease or therapy.
  • Adults 65 years of age or older who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23.
  • Adults ages 19 to 64 years with certain underlying medical conditions or other risk factors* who have not previously received a pneumococcal conjugate vaccine or whose previous vaccination history is unknown should receive a pneumococcal conjugate vaccine (either PCV20 or PCV15). If PCV15 is used, this should be followed by a dose of PPSV23.

*alcoholism, chronic heart/liver/lung disease, cigarette smoking, diabetes mellitus, chronic renal failure, nephrotic syndrome, immunodeficiency, iatrogenic immunosuppression, generalized malignancy, human immunodeficiency virus, Hodgkin disease, leukemia, lymphoma, multiple myeloma, solid organ transplants, congenital or acquired asplenia, sickle cell disease or other hemoglobinopathies, CSF leak, or cochlear implant.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.

June 2021

ACIP approved the following recommendations by majority vote at its June 24-25, 2021 meeting.

  • ACIP recommends 3-doses of Dengvaxia administered 6 months apart at month 0, 6, and 12, in persons 9-16 years of age with a laboratory confirmation of previous dengue infection and living in endemic areas.
  • ACIP affirms the updated MMWR Recommendations and Reports, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2021-22 Influenza Season.”
  • ACIP recommends a 2-dose [0, 7 days] intramuscular rabies vaccine series in immunocompetent persons <18 years of age for whom rabies vaccine pre-exposure prophylaxis (PrEP) is indicated.
  • ACIP recommends an intramuscular booster dose of rabies vaccine, as an alternative to a titer check, for immunocompetent persons <18 years of age who have sustained and elevated risk for only recognized rabies exposures (i.e., those in risk category #3 of rabies PrEP recommendations table).  The booster dose should be administered no sooner than day 21 but no later than 3 years after the 2-dose PrEP series.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.

February 2021

ACIP approved the following recommendations by majority vote at its February 24-25, 2021 meeting.

  • ACIP recommends a 2-dose [0, 7 days] intramuscular rabies vaccine series in immunocompetent persons ≥18 years of age for whom rabies vaccine pre-exposure prophylaxis (PrEP) is indicated.
  • ACIP recommends an intramuscular booster dose of rabies vaccine, as an alternative to a titer check, for immunocompetent persons ≥18 years of age who have sustained and elevated risk for only recognized rabies exposures (i.e., those in risk category #3 of rabies PrEP recommendations table).  The booster dose should be administered no sooner than day 21 but no later than 3 years after the 2-dose PrEP series.

These recommendations have been adopted by the CDC Director and will become official once published in MMWR.

Page last reviewed: November 19, 2021